Spotlight Poster Discussion 8 – Thursday, December 10, 2020: 2:15 pm – 3:30 pm
   
  Endocrine Resistance: Emerging Mechanisms and Therapies
PD8-01 Comprehensive genomic profiling (CGP) of metastatic invasive lobular carcinomas reveals heterogeneity in immune biomarkers and resistance alterations across biopsy sites
Sokol E, Jin DX, Ross J, Frampton GM, Oesterreich S. Foundation Medicine, Cambridge, MA; University of Pittsburgh, Pittsburgh, PA.
PD8-02 Kinome profiling of ER+ breast cancer PDXs identifies PKMYT1 as a marker of hormone independent growth and poor outcome
Chen A, Kim B-J, Chan DW, Singh P, Dobrolecki LE, Lei JT, Li S, Welm AL, Lewis MT, Ellis MJ. Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO; Huntsman Cancer Institute, Salt Lake City, UT.
PD8-03 A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer
Fu X, Pereira R, Qin L, De Angelis C, Nanda S, Shea M, Nardone A, Jeselsohn R, Cohen O, Wagle N, Rimawi M, Osborne CK, Schiff R. Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Boston, MA.
PD8-04 Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer
Jayaraman S, Kuffel MJ, Kalari KR, Thompson KJ, Tang X, Suman VJ, Bruinsma ES, Ciara O'Sullivan C, Wang L, Weinshilboum R, Ingle JN, Hawse JR, Goetz MP. Mayo Clinic, Rochester, MN.
PD8-05 Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
Haricharan S, Punturi N, Seker S, Devarakonda V, Kalra R, Chen C-H, Mazumder A, Li S, Primeau T, Ellis M, Kavuri S. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA; Baylor College of Medicine, Houston, TX; Washington University in St. Louis, St. Louis, MO; Washington University in St Louis, St Louis, MO.
PD8-06 Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
Hamilton EP, Wang JS, Pluard T, Johnston S, Morikawa AA, Dees CE, Jones RH, Haley B, Armstrong A, Cohen AL, Munster P, Wright G, Kayali F, Korpal M, Yu L, Cantagallo L, Destenaves B, Zhang Z, Gao L, Pipas MJ, Sahmouud T, Gualberto A, Juric D. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Florida Cancer Specialists, Sarasota, FL; Saint Luke’s Cancer Institute, Kansas City, MO; The Royal Marsden Hospital, London, United Kingdom; University of Michigan, Ann Arbor, MI; Linebarger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom; University of Texas Southwestern Medical Center, Dallas, TX; The Christie Hospital, Manchester, United Kingdom; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of California San Francisco, San Francisco, CA; Sarah Cannon Research Institute, Florida Cancer Specialists North, Saint Petersburg, FL; Sarah Cannon Research Institute, Tennessee Oncology, Sarasota, FL; H3 Biomedicine, Cambridge, MA; H3 Biomedicine, Cambridge, TN; Eisai Inc., Woodcliff Lake, NJ; Massachusetts General Hospital, Boston, MA.
PD8-07 Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer
Aftimos P, Maglakelidze M, Glaudemans AWJM, Hamilton E, Chap L, de Vries E, Menke-van der Houven van Oordt CW, Jager A, Dees EC, Cristofanilli M, Pegram M, Ulahannan S, Neven P, Bulat I, Rai R, Tao W, Jain S, Beelen AP, Sorrentino JA. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; LLC Arensia Exploratory Medicine, Tblisi, Georgia; University Medical Center Groningen, Groningen, Netherlands; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Beverly Hills Cancer Center, Beverly Hills, CA; Amsterdam UMC, location Vrije Universiteit Medical Center, Amsterdam, Netherlands; Erasmus MC Cancer Institute, Rotterdam, Netherlands; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; RH Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Stanford Women’s Cancer Center, Stanford, CA; Stephenson Cancer Center, Oklahoma City, OK; UZ Leuven, Leuven, Belgium; Arensia Exploratory Medicine Research Unit, Institute of Oncology, Chisinau, Republic of Moldova; G1 Therapeutics, Inc., Research Triangle Park, NC.
PD8-08 A Phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
Linden HM, Campone M, Bardia A, Ulaner GA, Gosselin A, Doroumian S, Pelekanou V, Celanovic M, Chandarlapaty S. University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA; Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Sanofi, Paris, France; Sanofi, Montpellier, France; Sanofi, Cambridge, MA.
PD8-09 Androgen and ESR1 mutant receptors mechanistically collaborate for overexpression of genes associated with poor outcomes in ER-positive metastatic breast cancer
Fuqua S, Gonzalez TL, Gu G, Herzog S, Rechoum Y, Beyer A, Edwards D, Lin H, Paul B, Kittler R, Weigel N, Grimm S, Coarfa C, Bawa-Khalfe T. Baylor College of Medicine, Houston, TX; UT Southwestern, Dallas, TX; University of Houston, Houston, TX.
PD8-10 Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study
Palmieri C, Linden H, Birrell S, Lim E, Schwartzberg LS, Rugo HS, Cobb P, Jain K, Vogel C, O’Shaughnessy JA, Getzenberg RH, Steiner MS, Brufsky A, Overmoyer B. The Clatterbridge Cancer Center NHS Foundation Trust, Liverpool, United Kingdom; University of Washington/ Seattle Cancer Care Associates, Seattle, WA; Wellend Health/Burside Hospital, North Adelaide, Australia; University of New South Wales, Australia and Garvan Institute of Medical Research, Darlinghurst, Australia; The West Clinic, Memphis, TN; University of California San Francisco, San Francisco, CA; Cancer Centers of Montana, Billings, MT; Ashland Bellefonte Cancer Center, Ashland, KY; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Veru Inc, Miami, FL; Magee-Womens's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA; Dana Farber Cancer Institute, Boston, MA.